Upcoming event


5α-Reductase inhibitors, Aanticoagulants, Antegrade ejaculation, Aquablation, Avanafil, Benign Prostatic Diseases, bipolar TURO, Bladder injury, Bladder outlet obstruction, Bladder trauma, BNC, BOO, BOOI, BPD, BPE, BPH, BPO, Chronic bacterial prostatitis, CP/CPPS, CPPS, Desmopressin, Detrusor, Detrusor hypocontractility, Dihydrotestosterone, Drug adherence, Drug therapy, Dutasteride, EAU, Ejaculation, Ejaculation preservation, Ejaculatory dysfunction, Endoscopic surgery, Epidemiology, Erectile dysfunction, Fexapotide triflutate, Fibrosis, Finasteride, Frequency volume chart, GL-XPS, GreenLight laser, Guidelines, Herbal medicines, HoLEP, Hypogonadism, Impaired contractility, Incontinence, Infertility, Inflammation, Inflammatory biomarkers, Innervation, IPP, IPSS, iTIND, Laparoscopy, Laser Bipolar, Laser prostatectomy, Laser therapy, LUT, LUTS, Major cardiac adverse event, Management of Non-Neurogenic LUTS incl. BPO, Medical therapy, Meta analysis, Meta regression, Metabolic syndrome, Microbiome, Micturition chart, Minimally invasive surgical therapy, minimally invasive techniques, Mirabegron, Monotherapies, Muscarinic antagonist, nitinol, Nocturia, Noninvasive, NX-1207, Overactive bladder, Pathogenesis, Pathophysiology, Patient satisfaction, Patient-reported outcome, Permixon, Pharmacology, Phenotypically directed multimodal management, Phosphodiesterase type 5 inhibitor, Phosphodiesterase type 5 inhibitors, Phytotherapy, Placebo effect, Plasmakinetic enucleation, Prospective study, Prostate, Prostate arterial embolisation, Prostate surgery, Prostate-specific antigen, Prostatectomy, Prostatic, Prostatic arterial embolization, Prostatic artery embolization, Prostatic hyperplasia, Prostatitis, PUL, Quality of life, Randomized trial, RASP, Remission, Retrograde ejaculation, Robotic, Robotic surgery, Robotics, Serenoa repens, Sexual Dysfunction, Sexual dysfunctions, Sildenafil, Simple prostatectomy, Solifenacin, Stem cells, Surgery, Surgical intervention, Systematic review, Tadalafil, Tamsulosin, Telomerase, Testosterone, ThuLEP, TmLRP, TUR syndrome, TURis, TURP, Ultrasonography, Underactive bladder, urethral implantable device, Urethral injury, Urethral trauma, Urinary Incontinence in Adults, Urinary nerve growth factor, Urinary sphincter, Urodynamics, Urolift, Vardenafil, Voiding, Voiding dysfunction, α-Adrenergic blocker, α-Adrenoceptor antagonists, α-Blocker, α-blockers, α1-Blockers
Show all

Adherence to Therapy for Lower Urinary Tract Symptoms: Don’t Mistake Association with Causation!

European Urology, Volume 68, Issue 3, September 2015, Pages 426-427

Re: Drug Adherence and Clinical Outcomes for Patients Under Pharmacological Therapy for Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia: Population-based Cohort Study

European Urology, Volume 68, Issue 2, August 2015, Pages 338-339

The Prostatic Urethral Lift Procedure: Enough Bang for the Buck?

European Urology 2015 May 19

Transurethral Resection of the Prostate for Benign Prostatic Obstruction: Will It Remain the Gold Standard?

European Urology, Volume 6, Issue 67, Pages 1097-1098

Re: Association Between Metabolic Syndrome and Severity of Lower Urinary Tract Symptoms: An Observational Study in a 4666 European Men Cohort

European Urology, Volume 67, Issue 5, May 2015, Pages 973-974

Maintaining a Healthy Balance: Targeting TERT to Stem Benign Prostatic Hyperplasia

European Urology, Volume 69, Issue 4, April 2016, Pages 555-556

Re: α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies

European Urology, Volume 69, Issue 6, June 2016, Pages 1091-1101

Is Combination Better than Escalation for Overactive Bladder Therapy?

European Urology, Volume 70, Issue 1, July 2016, Pages 146-147

α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies

European Urology 2016 Jan 28

Urodynamic Testing for Men with Voiding Symptoms Considering Interventional Therapy: The Merits of a Properly Constructed Randomised Trial

European Urology 2016 Feb 01

Do the Benefits of Phosphodiesterase Type 5 Inhibitors in Male Lower Urinary Tract Symptoms Go Beyond Improved Symptoms?

European Urology 2016 Feb 10

TRPM8 antagonists to treat lower urinary tract symptoms: don’t lose your cool just yet

BJU Int. , Volume 117, Issue 3, March 2016, Pages 384-385